Detalhe da pesquisa
1.
177Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(12): 1752-1763, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34793718
2.
Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
BMC Cancer
; 21(1): 597, 2021 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34030646
3.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med
; 376(2): 125-135, 2017 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28076709
4.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Eur J Nucl Med Mol Imaging
; 47(10): 2372-2382, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32123969
5.
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.
Anticancer Drugs
; 31(3): 216-222, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31977567
6.
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Oncologist
; 24(4): 463-474, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355775
7.
Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
Oncology
; 96(6): 273-289, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31018209
8.
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
Cancer Sci
; 109(1): 174-181, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055056
9.
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Oncologist
; 23(1): 16-24, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29038234
10.
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.
Neuroendocrinology
; 106(3): 211-220, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-28554173
11.
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Endocr Pract
; 24(3): 243-255, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29547049
12.
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(10): 1411-1422, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838862
13.
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Lancet
; 387(10022): 968-977, 2016 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26703889
14.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
N Engl J Med
; 371(3): 224-33, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25014687
15.
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Endocr Pract
; 22(9): 1068-80, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27214300
16.
Consensus on biomarkers for neuroendocrine tumour disease.
Lancet Oncol
; 16(9): e435-e446, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26370353
17.
Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.
Oncologist
; 20(10): 1123-31, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26306904
18.
Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
Invest New Drugs
; 33(2): 341-8, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25388939
19.
Everolimus for advanced pancreatic neuroendocrine tumors.
N Engl J Med
; 364(6): 514-23, 2011 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21306238
20.
Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
Chemotherapy
; 60(3): 143-50, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25766415